MedTrace Logo

Neurocognitive Deficit After Paediatric Transplantation: Understanding the Role of Environment and Physical Function

NCT07408713 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-02-20

No results posted yet for this study

Summary

Hematopoietic stem cell transplantation (HSCT) is a potentially life-saving treatment for children with relapsed or resistant leukemia and other life-threatening hematological and hereditary disorders. In Denmark, around 25 children undergo allogeneic HSCT every year, of these approximately 85-90% survive into adulthood.

The goal of this observational study is to learn about neurocognitive outcomes in children undergoing (HSCT) and to understand which clinical, physical, and environmental factors may affect neurocognitive development during the first year after transplant. The main questions it aims to answer are:

How does neurocognitive function change from before HSCT to one year after transplantation in pediatric patients?

Which clinical, physical, and environmental factors are linked to better or worse neurocognitive outcomes?

Participants will:

Complete neurocognitive tests before HSCT and at 1-year follow-up, covering intelligence, memory, attention, executive function, processing speed, and motor skills.

Undergo physical tests before HSCT, at hospital discharge, at 6-months follow-up, and at 1-year follow-up, including muscle strength, mobility, endurance, balance, and cardiopulmonary fitness (only at 1-year follow-up).

Wear activity trackers to measure physical activity and sedentary time during hospitalization at 6 months and 1-year post-HSCT.

Complete questionnaires about sleep, pain, quality of life, fatigue, family background, and exposure to outdoor and green spaces.

Have medical records reviewed for treatment-related side effects, immune recovery, inflammation, and pain management.

This study will help understand how neurocognitive function develops after HSCT in children and which factors (clinical, physical, or environmental) may support better recovery and well-being.

Conditions

  • HSCT
  • Pediatric Cancer
  • Pediatric Patients
  • Late Effect
  • Toxicity
  • Neurocognitive Dysfunction
  • Physical Function
  • Physical Capacity

Sponsors & Collaborators

  • Jascha Fonden

    collaborator OTHER

  • The Dagmar Marshall Foundation

    collaborator OTHER

  • Gangsted Foundation

    collaborator UNKNOWN

  • Rigshospitalet, Denmark

    lead OTHER

Eligibility

Min Age
0 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-15
Primary Completion
2031-12-31
Completion
2031-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07408713 on ClinicalTrials.gov